Serax and Decadron drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Serax (oxazepam) and Decadron (dexamethasone). Common drug interactions include apnoea among females and delirium among males.

The phase IV clinical study analyzes what interactions people have when they take Serax and Decadron. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Serax?

Serax has active ingredients of oxazepam. It is often used in stress and anxiety. eHealthMe is studying from 1,542 Serax users. Check the latest studies of Serax.

What is Decadron?

Decadron has active ingredients of dexamethasone. It is often used in multiple myeloma. eHealthMe is studying from 47,210 Decadron users. Check the latest studies of Decadron.



On Jul, 30, 2026

19 people who take Serax and Decadron together, and have interactions are studied.

Serax and Decadron drug interactions.

What are the common drug interactions of Serax and Decadron, by gender? *:

female:

  1. Apnoea (suspension of external breathing)
  2. Biliary dilatation
  3. Blood alkaline phosphatase increased
  4. Blood creatinine increased
  5. Blood lactate dehydrogenase increased
  6. Cardiac failure congestive
  7. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  8. Cough
  9. Death
  10. Drug ineffective

male:

  1. Delirium (wild excitement)
  2. Confusional state
  3. Haemoglobin decreased
  4. Malignant melanoma stage iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started)
  5. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  6. Oedema (fluid collection in tissue)
  7. Oedema peripheral (superficial swelling)
  8. Platelet count decreased
  9. Pulmonary embolism (blockage of the main artery of the lung)
  10. Disease progression

What are the common drug interactions of Serax and Decadron, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Pulmonary embolism (blockage of the main artery of the lung)

40-49:

n/a

50-59:

  1. Delirium (wild excitement)
  2. Confusional state
  3. Disease progression
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Hallucination (an experience involving the perception of something not present)
  6. Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)
  7. Brain compression
  8. Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
  9. Cerebral haemorrhage (bleeding within the brain)
  10. Malignant melanoma stage iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started)

60+:

  1. Death
  2. Apnoea (suspension of external breathing)
  3. Hyperbilirubinaemia (excess of bilirubin in the blood)
  4. Hypokalaemia (low potassium)
  5. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  6. Liver disorder (liver diseases)
  7. Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
  8. Parotid gland enlargement
  9. Proteinuria (presence of protein in the urine)
  10. Pulmonary oedema (fluid accumulation in the lungs)

What are the existing conditions these people have? *

  1. Ovarian Cancer (cancer of ovary): 3 people, 15.79%
  2. Screaming (a long loud piercing cry): 1 person, 5.26%
  3. High Blood Pressure: 1 person, 5.26%
  4. Cellulitis (infection under the skin): 1 person, 5.26%
  5. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 5.26%
  6. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 1 person, 5.26%
  7. Diarrhea: 1 person, 5.26%
  8. Fungaemia (fungi circulate in the blood): 1 person, 5.26%
  9. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 1 person, 5.26%
  10. Insomnia (sleeplessness): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Serax and Decadron?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Serax and Decadron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Serax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Decadron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Serax and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Decadron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on oxazepam and dexamethasone (the active ingredients of Serax and Decadron, respectively), and Serax and Decadron (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: